Clinical Report: New Gildeuretinol Findings From Retina Society
Overview
Recent findings from the TEASE program indicate that oral gildeuretinol may reduce the growth rate of atrophic lesions in Stargardt disease. The drug demonstrates a favorable safety profile with no serious adverse events related to treatment.
Background
Stargardt disease is a leading cause of inherited retinal degeneration, often resulting in significant vision loss. Current treatment options are limited, making the development of new therapies, such as gildeuretinol, critical.
Data Highlights
| Study | Findings |
|---|---|
| TEASE-1 | 30% reduction in the rate of growth of atrophic lesions |
| TEASE-2 | Decrease in deterioration of the ellipsoid zone |
| TEASE-2 | Functional benefit of 2 letters in low-luminance visual acuity |
| SAGA | 4-letter benefit in low-luminance vision |
| Safety | No serious adverse events related to gildeuretinol |
Key Findings
- Gildeuretinol is an oral medication designed to prevent retinol dimerization in Stargardt disease.
- TEASE-1 showed a 30% reduction in the growth rate of atrophic lesions in advanced disease.
- TEASE-2 indicated a decrease in deterioration of the ellipsoid zone in earlier-stage patients.
- Functional improvement of approximately 2 letters in low-luminance visual acuity was observed in TEASE-2.
- Safety profile of gildeuretinol was positive, with no serious adverse events reported.
Clinical Implications
Clinicians should consider the safety profile and efficacy data when discussing treatment options with patients.
Conclusion
The ongoing research into gildeuretinol is being evaluated in the phase 3 NORTHSTAR trial.
Related Resources & Content
- Kuppermann BD, Fan KC, Do DV, Retinal Physician, 2026 -- New Gildeuretinol Findings From Retina Society
- Kuppermann BD, Retinal Physician, 2026 -- Gildeuretinol Shows Positive Visual Signals in SAGA
- Ferrone PJ, Retinal Physician, 2026 -- TEASE Program Builds Case for Gildeuretinol in Stargardt
- JAMA Network, 2026 -- Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial
- Alkeus Pharma, 2026 -- Microsoft Word - Alkeus NORTHSTAR 1st patient dosed_06082026_FINAL
- retinal physician — Gildeuretinol Demonstrates Benefit in Low-luminance Visual Function
- Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
- Microsoft Word - Alkeus NORTHSTAR 1st patient dosed_06082026_FINAL
- Gildeuretinol Acetate vs Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The SAGA Randomized Clinical Trial - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.